Literature DB >> 24436110

Atypical cytologic diagnostic category in EUS-FNA of the pancreas: follow-up, outcomes, and predictive models.

Evan Alston1, Sejong Bae, Isam A Eltoum.   

Abstract

BACKGROUND: The objective of this study was to assess how atypical diagnostic category (ADC) is followed up, its outcomes, and the predictors that are associated with subsequent diagnosis of neoplasm/malignancy.
METHODS: We reviewed pancreatic endoscopic ultrasound fine-needle aspiration (EUS-FNA) with ADC and compared the rate of detection of neoplasms after a repeat FNA, a biopsy/resection, or a clinical follow-up following ADC. Logistic regression was used to determine the factors associated with the diagnosis of a neoplastic or a malignant lesion following ADC. Predictive probability for each case was calculated on the basis of the significant predictors, and whether it improved diagnostic performance was assessed.
RESULTS: Of 3832 cases that received pancreatic EUS-FNAs, 187 (4.9%) were ADC. A total of 93 neoplasms (55%), including 61 carcinomas (36%), were detected after an atypical cytologic diagnosis. Similar rates of detecting neoplasms were observed after repeat FNA or biopsy/resection but higher than after clinical follow-up. The presence of a mass, history of alcohol use, and absence of a history of pancreatitis were significant predictors of a higher rate of diagnosis of neoplasm. Weight loss and bile flow obstruction were more likely to be associated with higher rates of carcinoma. Predictive probability demonstrated a wide range of risk and changed the ambiguous diagnosis to informative in 30% of cases.
CONCLUSIONS: ADC of pancreas is associated with a high risk of benign and malignant neoplasms regardless of the method of follow-up. The presences of a mass, alcohol use, and absence of a history of pancreatitis are significant predictors of a diagnosis of neoplasm, whereas weight loss and bile duct obstruction are significant predictors of ductal carcinoma following an ADC.
© 2013 American Cancer Society.

Entities:  

Keywords:  EUS-FNA; diagnostic accuracy; guidelines; pancreas; predictive modeling

Mesh:

Year:  2014        PMID: 24436110     DOI: 10.1002/cncy.21389

Source DB:  PubMed          Journal:  Cancer Cytopathol        ISSN: 1934-662X            Impact factor:   5.284


  5 in total

Review 1.  Imaging modalities for characterising focal pancreatic lesions.

Authors:  Lawrence Mj Best; Vishal Rawji; Stephen P Pereira; Brian R Davidson; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2017-04-17

2.  Independent risk factors for true malignancy in atypical cytologic diagnostic category in EUS-FNA/FNB of the pancreas: A novel prediction model.

Authors:  Ping-Ping Zhang; Teng Wang; Shi-Yu Li; Li Li; Xiao-Ju Su; Pei-Yuan Gu; Yi-Ping Qian; Feng Li; Li Gao; Zhen-Dong Jin; Kai-Xuan Wang
Journal:  Endosc Ultrasound       Date:  2022 May-Jun       Impact factor: 5.275

Review 3.  Endoscopic ultrasonography guided-fine needle aspiration for the diagnosis of solid pancreaticobiliary lesions: Clinical aspects to improve the diagnosis.

Authors:  Hiroyuki Matsubayashi; Toru Matsui; Yohei Yabuuchi; Kenichiro Imai; Masaki Tanaka; Naomi Kakushima; Keiko Sasaki; Hiroyuki Ono
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

4.  Assessment of preoperative pancreatic biopsy, cytological/histological review of cell-block-specimens obtained by endoscopic ultrasound-guided fine-needle aspiration: Laboratory-based study.

Authors:  Natsuko Mizutani; Makoto Mochizuki; Masao Toki
Journal:  Diagn Cytopathol       Date:  2019-12-11       Impact factor: 1.582

5.  Development and validation of a clinical prediction model to estimate the probability of malignancy in solid pancreatic lesions and explore its value in the atypical diagnostic category after endoscopic ultrasound-guided fine-needle aspiration biopsy (EUS-FNA).

Authors:  Ning Wei; Rui Hua Shi; Ting Yu
Journal:  Transl Cancer Res       Date:  2020-11       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.